Enliven Therapeutics : EHA Corporate Deck FINAL 13JUN25 (1)

Published: 2025-06-13 06:12:10 ET ELVN

Published on 06/13/2025 at 06:12

Company Presentation

EHA Data Presentation June 13, 2025

3

Sam Kintz, M.B.A.

Helen Collins, M.D. Chief Medical Officer of Enliven Therapeutics

Damiette Smit, M.D.

4

Large CML Market Opportunity

Unique and

Complementary Design

Differentiated Efficacy & Safety Profile

Defined Regulatory Path

BCR::ABL1 TKIs have

historically generated ~$6B of combined annual sales, despite generic options

Potential $9B opportunity for differentiated TKIs in the U.S. alone, validated by successful Scemblix launch

ELVN-001 is the only selective ATP-competitive BCR::ABL1 TKI and has activity against asciminib-resistant mutations

PK supports QD dosing with or without food, and has low risk of DDIs

ELVN-001 efficacy, safety and tolerability profile in late line CML compare favorably to approved BCR::ABL1 inhibitors despite a more heavily pretreated patient population

Phase 1 data predicted performance in precedent registrational trials; biomarker endpoints allow for smaller, faster studies

Expected to initiate first ELVN-001 head-to-head pivotal trial in 2026

Enliven has a strong balance sheet expected to provide cash runway into late 2027

5

ATP = Adenosine triphosphate. BCR::ABL = Breakpoint cluster region-Abelson leukemia virus. CML = Chronic myeloid leukemia. DDI = Drug-drug interactions. QD = once daily. PK = Pharmacokinetics. TKI = Tyrosine kinase inhibitor. Note: U.S. CML market assumes branded pricing and is calculated based on historical sales while adjusting for current prevael nce and pricing. References: public company filings and announcements.

Conclusions from cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. ELVN-001 data reported on June 13th, 2025.

Disclaimer

Enliven Therapeutics Inc. published this content on June 13, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 13, 2025 at 10:11 UTC.